GANX 240816 1.00C (GANX240816C1000) Stock Options, News & Quotes

0.35
0.000.00%

15min DelayClose Aug 2 15:59 ET

0.00High0.00Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Trytosaveabit

Jul 9 06:03

Watching for Q4 data!

$Gain Therapeutics(GANX.US)$ Gain Therapeutics Inc - Topline Data to Be Presented Mid-August! No discontinuations or adverse events!

Jaguar8

Jun 29 14:33

NEWS : Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024

$Gain Therapeutics(GANX.US)$

Jaguar8

Jun 27 07:36

NEWS

$Gain Therapeutics(GANX.US)$
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease
Gain Therapeutics has presented data at the Federation of European Neuroscience Societies (FENS) Forum 2024 showing that their lead therapeutic candidate, GT-02287, has significantly improved cognitive function and activities of daily living in a preclinic...

Jaguar8

Jun 13 20:01

NEWS

$Gain Therapeutics(GANX.US)$
Gain Therapeutics Announces Pricing of $11.0 Million Public Offering

Jaguar8

May 30 06:16

NEWS

$Gain Therapeutics(GANX.US)$
Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024
Gain Therapeutics has announced that its late-breaking abstract on GT-02287, a clinical-stage GCase enhancer, has been accepted for presentation at the FENS Forum 2024 in Vienna. New data reveals improvements in cognitive performance in a preclinical model of GBA1 Parkinson’s disease. The presentation is sched...